Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom (NASDAQ: DXCM) announced the expansion of coverage for its Dexcom G7 Continuous Glucose Monitoring (CGM) System under Ontario's Drug Benefit (ODB) program. The coverage now extends to eligible Ontarians managing diabetes with insulin, impacting a significant portion of the estimated 1.7 million people living with diabetes in Ontario.
The Dexcom G7, recognized as the most accurate CGM and the #1 preferred glucose sensor by Canadian endocrinologists, offers unique features including a predictive urgent low alert, waterproof sensor, 30-minute warm-up time, and direct Apple Watch functionality. The expanded coverage makes Dexcom G7 the most covered CGM on government-funded programs in Ontario, available through ODB, ADP, private insurance, and NIHB programs.
Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched a groundbreaking AI-powered Smart Food Logging feature across its product portfolio. The feature is now available on both Stelo, the first FDA-cleared over-the-counter glucose biosensor, and Dexcom G7, making it the only prescription continuous glucose monitor in the U.S. with photo logging capability.
The innovative feature allows users to simply take a photo of their food in the app, where AI automatically identifies ingredients and populates meal descriptions. This launch is accompanied by several other technological enhancements, including Weekly Insights powered by GenAI, Oura integration for holistic biometric tracking, customizable target ranges in Dexcom G7, and a new Glucose Impact feature for better understanding of how various activities affect glucose levels.
Users can access these features by updating to the latest version of their respective apps on iOS and Android platforms.Dexcom (NASDAQ:DXCM) has announced the fourth season of its groundbreaking Dexcom U NIL program, exclusively for college athletes with diabetes. The 2025 roster features 21 total athletes, including 13 new members and 8 returning participants from various colleges across the United States.
The company hosted its first-ever Dexcom U Signing Day Camp in Baltimore, featuring Baltimore Ravens tight end Mark Andrews and NFL legend Mike Golic Sr. The program, launched in 2022, has impacted over 40 college athletes across 38 schools and 19 sports. All participants use Dexcom's continuous glucose monitoring (CGM) technology to manage their diabetes while competing at the collegiate level.
DexCom (NASDAQ:DXCM) has scheduled its second quarter 2025 earnings release and conference call for July 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time to review the quarterly performance.
Investors can access the conference call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114". A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.
Dexcom (NASDAQ: DXCM), a leader in real-time continuous glucose biosensing, has promoted Jake Leach to the role of president while maintaining his position as chief operating officer. Leach, who has over 21 years of leadership experience at Dexcom, has been instrumental in developing the company's biosensing platforms since their first commercial system launch.
In his COO role, which he has held since 2022, Leach oversees product development, global operations, R&D, quality management, regulatory and medical affairs. His expanded role as president will include additional oversight of Dexcom's corporate development and strategy efforts. CEO Kevin Sayer expressed strong confidence in Leach's ability to build upon his track record of innovation and achievement in metabolic health.
DexCom (DXCM) reported strong Q1 2025 financial results with revenue growing 12% year-over-year to $1.036 billion. The company saw U.S. revenue growth of 15% and international revenue growth of 7%. GAAP operating income reached $133.7 million, representing 12.9% of revenue.
Key developments include broader coverage with 2 of 3 largest PBMs now covering Dexcom CGM for diabetes patients, Stelo's launch on Amazon, and FDA clearance for the Dexcom G7 15 Day System. The company announced a $750 million share repurchase program and updated its 2025 guidance, projecting revenue of $4.60 billion (14% growth) with Non-GAAP Operating Margin of approximately 21%.
Dexcom (NASDAQ: DXCM) has announced the fourth season of Dexcom U, its unique Name, Image and Likeness (NIL) program for college athletes with diabetes. The program is launching its first nationwide search for new athletes to join its 2025 roster, with nominations open through May 23.
Selected athletes will join eight returning members at the Dexcom U Signing Day Camp this summer, hosted by Baltimore Ravens tight end Mark Andrews. Participants will receive access to Dexcom Continuous Glucose Monitoring (CGM) technology, exclusive events, and networking opportunities with collegiate and professional athletes.
The program aims to showcase athletes who manage diabetes while competing at high levels, using Dexcom G7 technology to monitor their glucose levels in real-time through smartphones and smartwatches. The selection committee will focus on candidates who can serve as role models and share inspiring stories with the next generation of youth athletes.
Dexcom (NASDAQ:DXCM) has received FDA clearance for its Dexcom G7 15 Day Continuous Glucose Monitoring System for people over 18 with diabetes in the United States. The new system boasts an impressive 15.5 days of wear time and superior accuracy with an overall MARD of 8.0%.
Key features include waterproof capability, direct Apple Watch connectivity, automated activity logging, and a 12-hour grace period for sensor replacement. The system also offers remote glucose sharing with caregivers and enhanced alert settings.
The company plans to launch Dexcom G7 15 Day in the second half of 2025 and is working with insulin pump partners to ensure compatibility with automated insulin delivery systems. Clinical data presented at the Advanced Technologies and Treatments for Diabetes conference in Amsterdam confirms G7 15 Day as the most accurate CGM for adults.
DexCom (NASDAQ:DXCM) has announced its upcoming first quarter 2025 earnings release and conference call schedule. The company will disclose its Q1 2025 financial results after market close on Thursday, May 1, 2025.
Management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the quarterly performance. Investors can access the call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID '9430114'. A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.